A Brain Imaging Study to Assess the Binding of MSP-2020 to Serotonin 5-HT2A Receptors in Healthy Male Adults

Phase 1 Recruiting 18 enrolled Otsuka Pharmaceutical Development & Commercialization, Inc.

NaSequentialOpen-labelTreatment

Summary

This study is to see how well MSP-2020 attaches to specific targets in the brain called serotonin type 2A receptors (5-HT2AR). This study will also look at how much of the study drug (and its metabolite) is in the blood and how long the study drug stays in the blood, as well as the safety of MSP 2020.

Timeline

Start: 2026-01-15
Primary completion: 2027-01-29
Completion: 2027-02-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MSP-2020	Unknown	—	Oral

Indications

No indication recorded.